Abu Dhabi achieved a medical milestone on January 5, 2026, with the UAE's first gene-therapy injection for inherited blood disorders. CASGEVY, utilizing CRISPR-Cas9, corrects faulty DNA in conditions ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Advanced engineered cell therapies require gene editing tools that are both precise and efficient. In recent years, CRISPR-Cas9 has emerged as the gold standard for editing genes with greater ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...